Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | STK17B | O94768 | 4/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 5/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.46 |
| ▸ | NEK2 | P51955 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280507 | 0.90 | SYK (0.63) | SYKCYP2C9MAP3K11NEK2JAK2 | |
| SCHEMBL2275268 | 0.86 | SYK (0.61) | SYKCYP2C9STK17BSTK17AMAP4K1 | |
| Hydrochloric Acid SCHEMBL2275144 | 0.85 | SYK (0.60) | SYKCYP2C9STK17BSTK17AMAP4K1 | |
| Trifluoroacetic Acid SCHEMBL2278432 | 0.85 | SYK (0.57) | SYKCYP2C9MAP3K11NEK2JAK2 | |
| SCHEMBL2279898 | 0.84 | SYK (0.62) | SYKCYP2C9STK17BSTK17AMAP4K1 | |
| SCHEMBL2276549 | 0.81 | SYK (0.69) | SYKCYP2C9STK17BSTK17AMAP4K1 | |
| SCHEMBL2282760 | 0.81 | SYK (0.69) | SYKCYP2C9MAP4K1MAP3K11AAK1 | |
| SCHEMBL2361559 | 0.80 | SYK (0.49) | SYKCYP2C9STK17BSTK17AMAP4K1 | |
| SCHEMBL2279703 | 0.80 | SYK (0.65) | SYKCYP2C9STK17BSTK17AMAP4K1 | |
| SCHEMBL12372271 | 0.79 | SYK (0.51) | SYKCYP2C9STK17BSTK17AMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | SYK 1/4885CYP2C9 3511/4885STK17B 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.